Abstract 2792
Background
Patient education is quite a current notion that has proved its efficiency. It has been shown as discussed in previous sections that it improves quite significantly treatment outcomes. Through education and support programs, patients health literacy is improved and so is the adherence of treatment. In this light, an education and support program was adapted at the Mohamed VI center for cancer treatment in Casablanca, with the following objectives: 1. Improve patient’s adherence to treatment 2. Increase early detection of chemotherapy side effects between cures 3. Improve quality of life and avoid toxic deaths.
Methods
In total, 96 patients were included into the program for a period of one year (February 2017- February 2018) and their satisfaction evaluated.
Results
In total, 96 patients were included into the program for a period of one year (February 2017- February 2018) and their satisfaction evaluated. 86,5% of the respondents were female while 13,5% were male. Of this, 70,8 % were literate while 29,2% were illetrate. Most of them, 57,2% had some awareness about cancer before they were included into the program while the rest , 42,8% had no cancer awareness. Most of the patients, 86,5% found that the videos and flyers were easy to understand while 80,2% reported that the same was helpful. 76% of the respondents admitted that the program had helped them become more proactive in their treatment. 78,1% of them were satisfied with the mobile phone calls in managing their complications at home without necessaroly coming to the hospital. 99% of the patients said that they would likely recommend the program to other patients. In overall, 87,5% of the patients were satisfied with the education program while only 3,1 % were dissatisfied. The rest of the respondents, 9,3% were neither satisfied nor dissatisfied.
Conclusions
At the end of the study, our findings were generally comparable to those in the literature and all the indicators were achieved. Therefore, this pilot program should be fully implemented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract